Reata Pharmaceuticals (NASDAQ:RETA) reported quarterly losses of $(1.16) per share which beat the analyst consensus estimate of $(2.10) by 44.76 percent. This is a 21.09 percent increase over losses of $(1.47) per share from the same period last year.
Piper Sandler Maintains Overweight on Intuit, Raises Price Target to $553
Piper Sandler analyst Arvind Ramnani maintains Intuit (NASDAQ:INTU) with a Overweight and raises the price target from $500 to $553.
